Therefore, rapid advances in the biologic and clinical understanding of CHIP may reveal a critical opportunity to improve patient care, especially in the era of new cancer research, focusing on the development of immunotherapies to prime, augment, or sustain immune responses. This evidence concerns the gene STUB1 and cancer.